Sun Pharma Agrees U.S. MFN Pricing For Two-Year Tariff Delay

Sun Pharma agreed to extend Most Favored Nation pricing to U.S. state Medicaid programs and future innovative-medicine launches, while securing a delay of Section 232 tariffs on innovative pharmaceutical products for more than two years; other terms remain confidential.